Anti-ROR1 antibody and ROR1-targeting engineered cells

Inventors

Golubovskaya, Vita • Wu, Lijun

Assignees

Caribou Biosciences Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11932703-B2

Patent

Publication Date

2024-03-19

Expiration Date


Abstract

The present invention is directed to a monoclonal mouse or humanized ROR1 antibody, or a single-chain variable fragment (scFv). The present invention is also directed to a mouse or humanized ROR1 chimeric antigen receptor (CAR) comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain.

Core Innovation

The invention relates to anti-human ROR1 monoclonal antibodies and antigen-binding fragments that bind ROR1 and include defined complementarity determining regions within variable heavy and variable light regions. The antibodies or antigen-binding fragments comprise a VH amino acid sequence that is at least 90% identical to SEQ ID NO: 2 and a VL amino acid sequence that is at least 90% identical to SEQ ID NO: 3.

The VH and VL CDRs are specified such that the VH CDR1 comprises the sequence TYA, the VH CDR2 comprises SEQ ID NO: 41, the VH CDR3 comprises SEQ ID NO: 42, the VL CDR1 comprises SEQ ID NO: 43, the VL CDR2 comprises the sequence RAN, and the VL CDR3 comprises SEQ ID NO: 45. The invention further encompasses engineered binding formats and constructs derived from the anti-ROR1 antibodies, including single-chain variable fragment (scFv) formats and humanized variants.

Defined scFv constructs and their sequence constraints are incorporated into a chimeric antigen receptor (CAR) architecture. The CAR architecture is described as an scFv–transmembrane domain–co-stimulatory domain (CD28 or 4-1BB)–activation domain (CD3ζ), including additional structural elements such as a hinge domain and signaling elements.

The document reports experimental validation of ROR1 binding and functional activity for the anti-ROR1 scFv-based CAR designs, including comparisons between different CAR co-stimulatory domains and between mouse and humanized scFv variants. Antibody binding to ROR1 is supported by Western blot, and ROR1 detection on ROR1-positive cells is supported by FACS.

Claims Coverage

The independent claims cover 1 inventive feature for a defined anti-human ROR1 antibody or antigen-binding fragment, and extend to derivative binding formats and engineered CAR constructs with defined signaling architecture.

Defined anti-human ROR1 antibody with VH/VL identity and specified CDR sequences

An anti-human ROR1 antibody or an antigen-binding fragment comprising VH with an amino acid sequence at least 90% identical to SEQ ID NO: 2 and VL with an amino acid sequence at least 90% identical to SEQ ID NO: 3, wherein a CDR1 of the VH comprises the sequence TYA, a CDR2 of the VH comprises SEQ ID NO: 41, a CDR3 of the VH comprises SEQ ID NO: 42, a CDR1 of the VL comprises SEQ ID NO: 43, a CDR2 of the VL comprises the sequence RAN, and a CDR3 of the VL comprises SEQ ID NO: 45.

The claims focus on precise definition of anti-human ROR1 binding specificity through VH/VL sequence identity thresholds and explicit CDR composition constraints, and extend this into scFv and CAR constructs with defined domain architecture and co-stimulatory domain options.

Stated Advantages

Not explicitly described in patent.

Documented Applications

Not explicitly described in patent.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.